Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with ezabenlimab in patients with advanced or metastatic solid tumors.
-
Enrollment
This study is not currently enrolling. -
Research Area
Clinical Cancer Research -
Sponsor
0019920593 The Hosp. For Sick Children Study Team